Patents by Inventor Yili Wang

Yili Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Interleukin converting enzyme inhibitors
    Publication number: 20040009966
    Abstract: The present invention relates to novel compounds, compositions comprising said compounds, and uses thereof, said compounds having the formula: 1
    Type: Application
    Filed: June 9, 2003
    Publication date: January 15, 2004
    Applicant: The Procter & Gamble Company
    Inventors: John August Wos, Yili Wang, Kofi Abeka Oppong, Steven Victor O'Neil, Michael Christopher Laufersweiler, David Lindsey Soper, Biswanath De, Thomas Prosser Demuth
  • Novel interleukin-1beta converting enzyme inhibitors
    Publication number: 20030236296
    Abstract: The present invention relates to interleukin-1&bgr; converting enzyme inhibitors having the formula: 1
    Type: Application
    Filed: June 9, 2003
    Publication date: December 25, 2003
    Applicant: The Procter & Gamble Company
    Inventors: John August Wos, David Lindsey Soper, Steven Victor O'Neil, Yili Wang, Kofi Abeka Oppong, Michael Christopher Laufersweiler, Jian Chen, Biswanath De, Thomas Prosser Demuth
  • Process for making epoxide intermediates
    Patent number: 6066751
    Abstract: It has been surprisingly discovered that the disadvantages of the lengthy literature procedures to synthesize 13,14-dihydro prostaglandin A, E, and F derivatives can be overcome using a novel Methyl 7-(2-hydroxy-5-(2-(2-oxiranyl)ethyl)-4-(1,1,2,2 tetramethyl-1-silapropoxy)cyclopentyl) heptanoate intermediate, which can be synthesized from commercially available Methyl 7-[3-(R)-hydroxy-5-oxo-1-cyclopent-1-yl] heptanoate. This novel intermediate can be coupled with oxygen, carbon, sulfur, and nitrogen nucleophiles, in the presence of a base or a Lewis acid, in a ring-opening process to provide 13,14-dihydro prostaglandin A, E, and F derivatives.
    Type: Grant
    Filed: September 4, 1998
    Date of Patent: May 23, 2000
    Assignee: The Procter & Gamble Company
    Inventors: John August Wos, Jack Snyder Amburgey, Jr., Mitchell Anthony deLong, Yili Wang, Haiyan George Dai, Biswanath De
  • Aromatic C.sub.16 -C.sub.20 -substituted tetrahydro prostaglandins useful as FP agonists
    Patent number: 5977173
    Abstract: The invention provides novel PGF analogs. In particular, the present invention relates to compounds having a structure according to the following formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, X, Y, and Z are defined below. This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof.The compounds of the present invention are useful for the treatment of a variety of diseases and conditions, such as bone disorders and glaucoma. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment for bone disorders and glaucoma using theses compounds or the compositions containing them.
    Type: Grant
    Filed: September 4, 1998
    Date of Patent: November 2, 1999
    Inventors: John August Wos, Mitchell Anthony deLong, Jack S. Amburgey, Jr., Biswanath De, Haiyan George Dai, Yili Wang